Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Change in Account Payables (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Change in Account Payables for 8 consecutive years, with -$1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 54.27% year-over-year to -$1.3 million, compared with a TTM value of -$3.0 million through Dec 2025, down 254.52%, and an annual FY2025 reading of -$3.0 million, down 254.52% over the prior year.
  • Change in Account Payables was -$1.3 million for Q4 2025 at Arcturus Therapeutics Holdings, up from -$5.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $11.8 million in Q1 2023 and bottomed at -$12.7 million in Q4 2023.
  • Average Change in Account Payables over 5 years is -$358150.0, with a median of -$1.2 million recorded in 2025.
  • The sharpest move saw Change in Account Payables plummeted 569.28% in 2022, then soared 26890.91% in 2023.
  • Year by year, Change in Account Payables stood at $1.8 million in 2021, then tumbled by 569.28% to -$8.4 million in 2022, then crashed by 50.76% to -$12.7 million in 2023, then soared by 76.94% to -$2.9 million in 2024, then soared by 54.27% to -$1.3 million in 2025.
  • Business Quant data shows Change in Account Payables for ARCT at -$1.3 million in Q4 2025, -$5.0 million in Q3 2025, and $4.4 million in Q2 2025.